Insider analysis from Monitor Deloitte on new commercial models for China’s tier 2 market

Growth and margins are slowing or declining in the top tier market. Expanding into the geographically dispersed and fragmented Tier 2 market and serving the market cost effectively are top agenda for MNCs. Patient affordability in Tier 2 is improving, lowering the entry barrier for MNC products. By 2011, the Chinese government had provided 95% of the population with access to insurance. The strong economy has also elevated income levels across the nation.

Read the PharmAsia News article "Insider Analysis from Monitor Deloitte on New Commercial Models for China's Tier 2 Market" (subscription is needed in order to view the article in full) 

Did you find this useful?